The markets opened strong on F&O expiry today despite some mixed global cues
The Nifty gained 47 points to close at 3,605.\n\n
Within days of announcing mega investments for building in Hyderabad its second data centre cluster in India, Amazon Web Services (AWS) on Monday said it is excited about the India market, where cloud adoption offers massive headroom for growth. Pledging its long-term commitment to the India market, AWS, Amazon's cloud computing unit, said it expects global uncertainties to accelerate the decisions by companies to opt for flexible, on-demand cloud infrastructure to pare costs, gain efficiencies and drive business innovation. "Cloud reacts well to uncertainty," Puneet Chandok, president - commercial business, AWS India and South Asia, Amazon Internet Services Pvt Ltd (AISPL) told PTI.
10 non-bank and non-finance stocks from the BSE500 Index universe that offer an optimal blend of low valuation, reasonably robust revenue and earnings growth in recent quarters, a strong balance sheet, and most importantly, positive cash flow from their operations.
The Sensex opened past the 8,200-mark at 8,208 as against Wednesday's close of 8,189 and later rallied smartly to a high of 8,252.
The US Food and Drug Administration had in February approved Johnson & Johnson's COVID-19 vaccine that works with just one dose for emergency use.
With rains once again lashing Mumbai, the Sensex opened weak and is now down 20 points at 7616. Nifty is down 8 points at 2304.
The index touched a low of 14,026, before settling with a loss of 168 points at 14,041.
The Sensex opened marginally (six points) higher at 5,657. Weakness in Infosys and Dr.Reddy's in early morning deals pulled down the index to an intra-day low of 5,623.\n\n
Favipiravir is the only oral anti-viral treatment approved in India for potential treatment of patients with mild to moderate Covid-19 disease.
Being a successful investor is all about making the most prudent investment decisions, even if they are dull and boring.
Indian drugmakers' domestic sales of ready-to-take medicines in January-March could be lower than expected as distributors suspended stocking in anticipation of a new value-added tax system coming into force, analysts and industry members said.\n\n\n\n
The markets opened in the positive terrain after seeing a flat close yesterday
The markets opened flat on the back of weak Asian and US cues
Benchmark indices Sensex and Nifty retreated from over one-week highs to close lower on Wednesday due to profit booking in banking, IT and metal stocks amid weak global trends. After a two-day rally, the 30-share BSE Sensex dropped by 90.99 points or 0.16 per cent to settle at 57,806.49 in volatile trade. As many as 19 of its constituents declined while 11 advanced. The broader Nifty slipped by 19.65 points or 0.11 per cent to close at 17,213.60 with 31 of its stocks ending in the red.
The Sensex opened with a positive gap of 20 points at 10,133.
After exhibiting high volatility in early trades, the Sensex closed with a marginal loss of 22 points at 9,849.
Late selling in the market saw the Sensex close seven points lower at 9,374.
The Sensex is holding on to its gains on steady gains in techs, PSUs and heavyweights, and is now up 32 points
'The correction could take two to three months and traders need to be careful.' 'For investors, this could be a good time to nibble in.'
Domestic pharma major Panacea Biotec in collaboration with Russian sovereign wealth fund Russian Direct Investment Fund (RDIF) has begun the production of 'Sputnik V' COVID-19 vaccine in India, according to a joint statement issued.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
Shree Cement beats ACC in market value, Lupin ahead of Dr Reddy's Labs
The Sensex opened on a positive note at 7,556 and soon gathered momentum to rise above the 7,600-mark.
The markets displayed volatility with the Sensex clocking a high of 6,587 and a low of 6,509.
IT sector's trading multiples hit post-Lehman lows, providing good entry points.
The BSE Sensex opened with a positive gap of 10 points at 5,179. Fresh buying in the markets led the index spurt to a high of 5,204. The index is now at 5,195, up 26 points. The Nifty is up 7 points at 1,634.
Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.
The Sensex rallied to a new high of 10,238, and finally closed with a gain of 56 points at 10,224.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances